{
  "id": 19539646,
  "title": "Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint",
  "url": "https://urgent.news/2026/11/11/novel-glucagon-glp-1-agonist-meets-cardiovascular-safety-endpoint",
  "topic": "culture",
  "section": "Culture",
  "published": "2026-11-11T18:07:05.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/aha/123835"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- Survodutide, an investigational glucagon receptor and GLP-1 receptor dual agonist, was safe for patients with obesity and either established cardiovascular disease (CVD), chronic kidney disease (CKD), or increased risk of CVD...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}